share_log

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment For Phase 3 Trial Of APX3330 In Diabetic Retinopathy; Agreement Reached On Primary Endpoint And Phase 3 Trial Design

Opus Genetics获得FDA在特殊协议评估下的协议,用于APX3330在糖尿病视网膜病变中的3期临床试验;达成初级终点和3期临床试验设计的协议。
Benzinga ·  2024/12/19 21:06

Agreement Reached on Primary Endpoint and Phase 3 Trial Design

达成了关于主要终点和第三阶段试验设计的协议

Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering

口服APX3330是一项可供合作的晚期临床资产

FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).

密歇根州法明顿山,2024年12月19日(全球新闻网)-- Opus Genetics, Inc.(纳斯达克:IRD)是一家临床阶段的眼科生物技术公司,致力于开发治疗遗传性视网膜疾病(IRD)的基因疗法和用于治疗其他眼科疾病的小分子药物,今天宣布与美国食品药品监督管理局(FDA)达成了关于针对口服APX3330治疗中度至重度非增殖性糖尿病视网膜病(NPDR)的第三阶段临床试验的特别协议评估(SPA)。

The SPA agreement reflects that the proposed Phase 3 trial design, endpoints, and planned analyses will be adequate to support a New Drug Application (NDA) submission for treatment of NPDR, subject to a successful outcome of the trial and review of all data in the NDA. The agreed primary endpoint is a reduction in 3-step or greater worsening on the binocular diabetic retinopathy severity scale (DRSS) score, compared to placebo. In the previous Phase 2 ZETA-1 trial, oral APX3330 showed the potential to slow or prevent clinically meaningful progression of DR and demonstrated a favorable safety profile.

SPA协议反映出,提议的第三阶段试验设计、终点和计划分析将足以支持针对NPDR的新药申请(NDA)提交,前提是试验取得成功且审查NDA中的所有数据。达成的主要终点是与安慰剂相比,在双眼糖尿病视网膜病严重程度量表(DRSS)评分上减少3级或更大程度的恶化。在之前的第二阶段ZETA-1试验中,口服APX3330显示出减缓或防止DR临床显著进展的潜力,并展示了良好的安全性特征。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发